Nektar Therapeutics (NASDAQ:NKTR)
CAPS Rating:
A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
0
bradistheman
(24.49)
Submitted: 8/25/2006 12:58:27 AM :
Start Price:
$17.11
NKTR Score:
-68.01
makers of the new insulin inhaler, to be advertised and introduced to the american market this september, should see a bump when the masses start to buy.
Recs
1
stratton6
(98.84)
Submitted: 6/29/2006 4:04:27 PM :
Start Price:
$17.62
NKTR Score:
-71.98
NKTR has a strong patent position on pegylation technology. They provide both the reagents and service based research technology for pegylation of biologics and small molecules. They are also one of the only companies in the US where GMP peg materials can be purchased.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 41 - 42 of 42 : « Previous 1 2 3